Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients
Current Oncology · 2023
DOI: 10.3390/curroncol30080524 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2023. Verfasst von Takeshi Okamoto und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
The safety and effectiveness of chemotherapy in elderly patients with biliary tract cancer (BTC) remain unclear. Therefore, we retrospectively reviewed patients who underwent chemotherapy for locally advanced, metastatic, or recurrent BTC at our institution from January 2016 to December 2021. Of the 283 included patients, 91 (32.5%) were aged 75 years or older when initiating chemotherapy. Elderly patients were more likely than non-elderly patients to receive monotherapy with gemcitabine or S-1 (58.7% vs. 9.4%, p < 0.001) and were less likely to experience grade 3–4 toxicities (55.4% vs. 70.2%, p = 0.015). The rates of termination due to intolerance (6.5% vs. 5.8%, p = 0.800) and transition to second-line chemotherapy (39.1% vs. 40.3%, p = 0.849) were similar between groups. In the overall cohort, age was not an independent predictor of overall survival (OS). Within the elderly cohort, there were no differences in severe adverse events between patients receiving monotherapy and combination therapy (50.0% vs. 63.2%, p = 0.211). Median OS was longer in the combination therapy group (10.4 vs. 14.1 months; p = 0.010); however, choice of monotherapy was not an independent predictor of overall survival. Monotherapy appears to be a viable alternative in selected elderly BTC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Biliary-Pancreatic Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan.
- Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan.
ORCID-Profile: Takeshi Okamoto, Tsuyoshi Takeda, Takashi Sasaki, Tsuyoshi Hamada, Takafumi Mie, Akiyoshi Kasuga, Naoki Sasahira
Zitieren
APA
Okamoto, T., Takeda, T., Sasaki, T., Hamada, T., Mie, T., Ishitsuka, T., Yamada, M., Nakagawa, H., Hirai, T., Furukawa, T., Kasuga, A., Ozaka, M., & Sasahira, N. (2023). Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. Current Oncology. https://doi.org/10.3390/curroncol30080524
Vancouver
Okamoto T, Takeda T, Sasaki T, Hamada T, Mie T, Ishitsuka T, et al. Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients. Current Oncology. 2023. doi:10.3390/curroncol30080524
BibTeX
@article{Okamoto2023,
author = {Okamoto, Takeshi and Takeda, Tsuyoshi and Sasaki, Takashi and Hamada, Tsuyoshi and Mie, Takafumi and Ishitsuka, Takahiro and Yamada, Manabu and Nakagawa, Hiroki and Hirai, Tatsuki and Furukawa, Takaaki and Kasuga, Akiyoshi and Ozaka, Masato and Sasahira, Naoki},
title = {Safety and Effectiveness of Chemotherapy in Elderly Biliary Tract Cancer Patients},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30080524}
}
EUVIMED